TILL TRANSAKTIONER
Hälsovård

Building a leading one-stop ambulatory cancer center

SIAMH has successfully registered the offer document, launched an IPO and raised US$19.5 million.

SIAMH is a one-stop outpatient diagnostics and treatment center for cancer, neurogenerative and cardiovascular diseases in Singapore.

Oaklins’ team in Singapore acted as sponsor, issue manager, underwriter and placement agent in this transaction.

Prata med transaktionsteamet

Mark Liew

Partner
Singapore, Singapore
Oaklins PrimePartners

Relaterade transaktioner

MEDIK Hospital Design Group has been acquired by STERIS
Bygg- & tekniktjänster | Hälsovård

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Lär dig mer
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Hälsovård

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Lär dig mer
Banook, backed by Motion Equity, has acquired Fluidda
Hälsovård | TMT

Banook, backed by Motion Equity, has acquired Fluidda

Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.

Lär dig mer